PMC:7556165 / 71328-71683
Annnotations
LitCovid-sample-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T196 | 129-136 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T398 | 67-75 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T422 | 0-355 | Sentence | denotes | Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017). |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 1965 | 76-84 | Species | denotes | patients | Tax:9606 |
| 1966 | 316-324 | Species | denotes | patients | Tax:9606 |
| 1971 | 210-216 | Chemical | denotes | rhACE2 | |
| 1973 | 67-75 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1974 | 330-334 | Disease | denotes | ARDS | MESH:D012128 |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T459 | 129-136 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T420 | 67-75 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T421 | 330-334 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1965 | 76-84 | Species | denotes | patients | Tax:9606 |
| 1966 | 316-324 | Species | denotes | patients | Tax:9606 |
| 1971 | 210-216 | Chemical | denotes | rhACE2 | |
| 1973 | 67-75 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1974 | 330-334 | Disease | denotes | ARDS | MESH:D012128 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T422 | 0-355 | Sentence | denotes | Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017). |